Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allergan, Inc.
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.
GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Site Specific
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- MAP Pharmaceuticals, Inc. (MAPP)
- Oculex Pharmaceuticals, Inc.
- SkinMedica, Inc.